Pharmacogenomics (PGx) Results and Clinical Data of Established Patients with Liver Disease to Assess Current and Future Therapeutic Relevance of PGx Testing

Overview

About this study

The goal of this study is to examine the current and (potential) future therapeutic relevance of PGx testing in established patients with liver disease seen in the Division of Gastroenterology/Hepatology, in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of medications.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

An established liver disease patient seen in the Division of Gastroenterology and Hepatology.
Patients must be currently taking at least 5 prescribed medications.
An established Mayo Clinic patient within a Division of Gastroenterology and Hepatology. (Gastroenterology and Hepatology is piloting PGx testing with the Center for Individualized Medicine, seeking clinical information from emerging PGx testing technologies available in CLIA/CAP laboratories.)
Patient is age 18 or above.
Patients must understand and provide written informed consent and HIPAA authorization prior to initiation of any study-specific procedures.
Patient is willing to engage in a medication assessment as part of their clinical visit preparation (when needed).

Exclusion Criteria:

Patient with uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Konstantinos Lazaridis, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Konstantinos Lazaridis, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials